XALKORI PASS Survey

• Research type

  Research Study

• Full title

  “A cross-sectional Study to Evaluate the Effectiveness of XALKORI Patient Information Brochure among Non-small Cell Lung Cancer (NSCLC) Patients Receiving XALKORI treatment in Europe” (hereinafter the patient survey)

• IRAS ID

  186591

• Contact name

  Huang Kui ,

• Contact email

  kui.huang@pfizer.com

• Sponsor organisation

  Pfizer

• Duration of Study in the UK

  0 years, 9 months, 1 days

• Research summary

  The objective of the patient survey is to evaluate the effectiveness of the XALKORI PIB (Patient Information Brochure) with a survey. The study will assess whether the Patients treated with XALKORI, read, understood, and utilized the XALKORI PIB.\n

• REC name

  North West - Preston Research Ethics Committee

• REC reference

  16/NW/0362

• Date of REC Opinion

  29 Apr 2016

• REC opinion

  Favourable Opinion